scholarly journals Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database

2017 ◽  
Vol 24 (10) ◽  
pp. 505-518 ◽  
Author(s):  
Patrick Petrossians ◽  
Adrian F Daly ◽  
Emil Natchev ◽  
Luigi Maione ◽  
Karin Blijdorp ◽  
...  

Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. While diagnostic and therapeutic methods have advanced, little information exists on trends in acromegaly characteristics over time. The Liège Acromegaly Survey (LAS) Database, a relational database, is designed to assess the profile of acromegaly patients at diagnosis and during long-term follow-up at multiple treatment centers. The following results were obtained at diagnosis. The study population consisted of 3173 acromegaly patients from ten countries; 54.5% were female. Males were significantly younger at diagnosis than females (43.5 vs 46.4 years; P < 0.001). The median delay from first symptoms to diagnosis was 2 years longer in females (P = 0.015). Ages at diagnosis and first symptoms increased significantly over time (P < 0.001). Tumors were larger in males than females (P < 0.001); tumor size and invasion were inversely related to patient age (P < 0.001). Random GH at diagnosis correlated with nadir GH levels during OGTT (P < 0.001). GH was inversely related to age in both sexes (P < 0.001). Diabetes mellitus was present in 27.5%, hypertension in 28.8%, sleep apnea syndrome in 25.5% and cardiac hypertrophy in 15.5%. Serious cardiovascular outcomes like stroke, heart failure and myocardial infarction were present in <5% at diagnosis. Erythrocyte levels were increased and correlated with IGF-1 values. Thyroid nodules were frequent (34.0%); 820 patients had colonoscopy at diagnosis and 13% had polyps. Osteoporosis was present at diagnosis in 12.3% and 0.6–4.4% had experienced a fracture. In conclusion, this study of >3100 patients is the largest international acromegaly database and shows clinically relevant trends in the characteristics of acromegaly at diagnosis.

2000 ◽  
Vol 192 (3) ◽  
pp. 165-172 ◽  
Author(s):  
Mieko Sato ◽  
Masaaki Suzuki ◽  
Takeshi Oshima ◽  
Masaki Ogura ◽  
Akira Shimomura ◽  
...  

Endocrine ◽  
2015 ◽  
Vol 51 (2) ◽  
pp. 308-316 ◽  
Author(s):  
Cinzia Castellani ◽  
Giuseppe Francia ◽  
Luca Dalle Carbonare ◽  
Marcello Ferrari ◽  
Elena Viva ◽  
...  

2001 ◽  
Vol 55 (3) ◽  
pp. 245-246 ◽  
Author(s):  
Yuichi Inoue ◽  
Kazuyoshi Nanba ◽  
Genni Hazama ◽  
Kokichi Takata ◽  
Heii Arai

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Joanna Wojtasik-Bakalarz ◽  
Zoltan Ruzsa ◽  
Tomasz Rakowski ◽  
Andreas Nyerges ◽  
Krzysztof Bartuś ◽  
...  

The most relevant comorbidities in patients with peripheral artery disease (PAD) are coronary artery disease (CAD) and diabetes mellitus (DM). However, data of long-term follow-up of patients with chronic total occlusion (CTO) are scarce. The aim of the study was to assess the impact of CAD and DM on long-term follow-up patients after superficial femoral artery (SFA) CTO retrograde recanalization. In this study, eighty-six patients with PAD with diagnosed CTO in the femoropopliteal region and at least one unsuccessful attempt of antegrade recanalization were enrolled in 2 clinical centers. Mean time of follow-up in all patients was 47.5 months (±40 months). Patients were divided into two groups depending on the presence of CAD (CAD group: n=45 vs. non-CAD group: n=41) and DM (DM group: n=50 vs. non-DM group: n=36). In long-term follow-up, major adverse peripheral events (MAPE) occurred in 66.6% of patients with CAD vs. 36.5% of patients without CAD and in 50% of patients with DM vs. 55% of non-DM subjects. There were no statistical differences in peripheral endpoints in both groups. However, there was a statistically significant difference in all-cause mortality: in the DM group, there were 6 deaths (12%) (P value = 0.038). To conclude, patients after retrograde recanalization, with coexisting CTO and DM, are at higher risk of death in long-term follow-up.


2008 ◽  
Vol 190 (3) ◽  
pp. 800-808 ◽  
Author(s):  
Luciano Tarantino ◽  
Giampiero Francica ◽  
Ignazio Sordelli ◽  
Pasquale Sperlongano ◽  
Domenico Parmeggiani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document